MGI Pharma, Inc. (Nasdaq: MOGN),
is an oncology-focused biopharmaceutical company that acquires,
develops and commercializes proprietary pharmaceutical products.
Since 1996, Taglich Brothers has followed the Company when it
had a market capitalization of less than $65 Million. Today, MGI
Pharma is an emerging player in the oncology space with a market
capitalization close to $1 Billion. Participating in this
offering is just one example of how Taglich Brothers is
committed to a company, even when they out-grow our microcap
specialization.
The information
contained herein does not constitute a solicitation of any order
to buy or sell any securities. The information provided herein may
be displayed and printed for your personal, noncommercial use
only. You may not reproduce, retransmit, distribute, disseminate,
sell, publish, broadcast or circulate the information to anyone,
without the express written consent of Taglich Brothers, Inc.
